SCPX Stock Overview Through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Scorpius Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Scorpius Holdings Historical stock prices Current Share Price US$0.27 52 Week High US$106.00 52 Week Low US$0.25 Beta -0.26 1 Month Change -13.92% 3 Month Change -62.22% 1 Year Change -99.64% 3 Year Change -99.95% 5 Year Change -99.92% Change since IPO -100.00%
Recent News & Updates
Scorpius Holdings Announces Reverse Stock Split to Maintain NYSE Compliance Jan 17 Scorpius Holdings, Inc. has filed a Follow-on Equity Offering. Dec 28
Scorpius Holdings, Inc. announced that it expects to receive $12.05 million in funding Dec 07
Scorpius Holdings, Inc. announced delayed 10-Q filing Aug 16
Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million. Aug 08
NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock Jul 30
See more updates
Scorpius Holdings Announces Reverse Stock Split to Maintain NYSE Compliance Jan 17 Scorpius Holdings, Inc. has filed a Follow-on Equity Offering. Dec 28
Scorpius Holdings, Inc. announced that it expects to receive $12.05 million in funding Dec 07
Scorpius Holdings, Inc. announced delayed 10-Q filing Aug 16
Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million. Aug 08
NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock Jul 30
Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter Jul 24 Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Jul 20
Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility Jul 19 NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide Jun 18
Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024 Jun 02
Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024 May 31
Scorpius Holdings, Inc. Provides Non-Compliance Update May 25 Scorpius Holdings, Inc. announced delayed 10-Q filing May 18
Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million. May 15
Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million. May 04
Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc. May 03
Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide Apr 30
Scorpius Holdings Announces Receipt of Filing Delinquency Notification Apr 23 Scorpius Holdings, Inc. announced delayed annual 10-K filing Apr 02
Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023 Mar 07
Price target decreased by 9.1% to US$10.00 Feb 15
Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary Feb 02
NightHawk Biosciences, Inc. Announces Executive Appointments Jan 08 Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK). Dec 28
NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million. Dec 20
NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding Dec 13
NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million. Dec 10 NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million. Dec 09
NightHawk Biosciences, Inc. announced delayed 10-Q filing Nov 17
NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023 Aug 25
NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022 Jul 29
Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board Apr 20 Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock Feb 04
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110 Jan 13
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation Dec 28
Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc. Dec 23
Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats Dec 01
Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020) Nov 12
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation Sep 02
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary Aug 27
Price target decreased to US$21.83 Aug 25
Price target decreased to US$23.83 Aug 18
Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020) Aug 12
Consensus forecasts updated Jun 07
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients Jun 05
Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting May 21
Independent Lead Director recently sold US$205k worth of stock May 19
Consensus forecasts updated May 15
Consensus revenue estimates fall to US$1.98m May 13
Heat Biologics names Anthony Manning as chief scientific advisor May 10
Price target decreased to US$24.67 May 07 Shareholder Returns SCPX US Biotechs US Market 7D -27.9% 2.0% 2.4% 1Y -99.6% -4.1% 25.0%
See full shareholder returns
Return vs Industry: SCPX underperformed the US Biotechs industry which returned -4.1% over the past year.
Return vs Market: SCPX underperformed the US Market which returned 25% over the past year.
Price Volatility Is SCPX's price volatile compared to industry and market? SCPX volatility SCPX Average Weekly Movement 24.7% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.3%
Stable Share Price: SCPX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCPX's weekly volatility has decreased from 37% to 25% over the past year, but is still higher than 75% of US stocks.
About the Company Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
Show more Scorpius Holdings, Inc. Fundamentals Summary How do Scorpius Holdings's earnings and revenue compare to its market cap? SCPX fundamental statistics Market cap US$1.34m Earnings (TTM ) -US$29.66m Revenue (TTM ) US$10.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SCPX income statement (TTM ) Revenue US$10.04m Cost of Revenue US$19.14m Gross Profit -US$9.09m Other Expenses US$20.57m Earnings -US$29.66m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.09 Gross Margin -90.52% Net Profit Margin -295.27% Debt/Equity Ratio 8.4%
How did SCPX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 03:04 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Scorpius Holdings, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Justin Zelin B. Riley Securities, Inc. Kristen Kluska Cantor Fitzgerald & Co.
Show 4 more analysts 
